Dogma holds that plasma cells, as opposed to B cells, cannot bind antigen because they have switched from expression of membrane-bound immunoglobulins (Ig) that constitute the B-cell receptor (BCR) to ...
IGM Biosciences announced they are halting the development of two investigational drugs for autoimmune and inflammatory diseases, imvotamab (an IgM-based CD20 X CD3 bispecific antibody T cell engager) ...
Natural IgM, a pentameric, polyreactive antibody, is mainly secreted by peritoneal B1 B cells and recognizes and binds self antigens such as phospholipids. The unique structure of natural IgM allows ...
IGM Biosciences ended last year laying off staff and streamlining its cancer pipeline. Now, the company has become the latest to join a hot trend in cell therapy biotech—pivoting from oncology to ...
Sanofi has scrapped its collaboration with IGM Biosciences, eliminating the biotech’s last program in the process. IGM responded by laying off 80% of its staff and closing most of its lab and office ...
MOUNTAIN VIEW, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company committed to developing and delivering medicines to treat patients with ...
IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies ...
The country is seeing a massive dengue outbreak as thousands of cases are being reported monthly. This is a mosquito-borne illness that begins in the monsoon(mosquito ...
iShares Expanded Tech Sector ETF provides access to technology stocks, including the Magnificent 7, at a relatively cheap price. The GICS reclassification in 2018 broadened the Communication Services ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback